Emergent Biosolutions (EBS.N) said on Wednesday it would resume production of Johnson & Johnson's (JNJ.N) COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.
COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated.
"We are proud to be resuming production of bulk COVID-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners," Chief Executive Officer Robert Kramer said. The Wall Street Journal, which first reported the news, cited a letter from the U.S. Food and Drugs Administration saying the agency had no objections with the plant resuming manufacturing.
U.S. authorities in April halted operations at the Baltimore plant following a discovery that ingredients from AstraZeneca'sAn FDA inspection had also turned up a long list of sanitary problems and bad manufacturing practices. The facility could make as many as 120 million doses a month at full capacity, but the finished doses might not be available until this fall, the Journal said, citing a source.Reporting by Aishwarya Nair and Maria Ponnezhath in Bengaluru; Editing by Subhranshu Sahu and Ramakrishnan M.Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Covid-19: Health Trusts cancel surgeries as Covid admissions riseThe chief medical officer says the health service is operating under 'huge pressures'.
Leer más »
Some people are seeking out a second dose of Covid-19 vaccine after getting J&J shotJason Gallagher, an infectious disease pharmacist in Philadelphia had gotten the Johnson & Johnson Covid-19 vaccine through a clinical trial in November, but this summer he didn't like the direction Covid-19 cases were taking due to variants.
Leer más »
Pfizer Raises Full-Year Outlook on Covid-19 Vaccine SalesThe pharmaceutical company’s Covid-19 vaccine co-developed with BioNTech contributed $7.8 billion to Pfizer’s total sales of $18.98 billion in the latest quarter.
Leer más »
LA County COVID-19 hospitalizations nearly double in 2 weeksLos Angeles County is seeing an uptick in COVID-19-related hospitalizations, with the number of patients nearly doubling over the last two weeks, health officials said.
Leer más »
Pfizer data suggest third dose of Covid-19 vaccine 'strongly' boosts protection against Delta variantA third dose of the Pfizer/BioNTech Covid-19 vaccine can 'strongly' boost protection against the Delta variant -- beyond the protection afforded by the standard two doses, suggests new data released by Pfizer on Wednesday.
Leer más »